NewsVandana Singh
Sagimet Biosciences
SGMT · NASDAQ
$9.74+$0.88 (+9.93%)TodayMarket closed ·
Prev close $8.86
Latest news
- NewsTim Melvin
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
- Press releaseGlobe Newswire
Sagimet Biosciences Receives FDA “Study May Proceed” Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients
- Press releaseGlobe Newswire
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
- News
UK's MHRA Says Resmetirom (Rezdiffra) Authorized To Treat Metabolic Dysfunction-Associated Steatohepatitis In Adults
- Press releaseGlobe Newswire
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
- NewsVandana Singh
Why Is Sagimet Biosciences Stock Trading Higher On Monday?
- News
Sagimet Biosciences Plans To Initiate Phase 3 Clinical Trial Of Denifanstat In Moderate To Severe Acne Patients For US In H2 2026
- Press releaseGlobe Newswire
Sagimet Biosciences Provides Strategic and Corporate Updates
- Press releaseGlobe Newswire
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
- Press releaseGlobe Newswire
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
- Press releasePRNewswire
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
- News
Sagimet Reports MASH Combo Data, Eyes Phase 2 for Liver Treatment
- Press releaseGlobe Newswire
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
- Press releasePRNewswire
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
- Press releasePRNewswire
Ascletis Completes Denifanstat (ASC40) Pre-NDA Consultation with China National Medical Products Administration
- NewsVandana Singh
Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releasePRNewswire
Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints
- NewsAvi Kapoor
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
- Press releasePRNewswire
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.